Solriamfetol: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France) and TLV (Sweden) recommended or restricted solriamfetol, while ZIN (Netherlands) did not recommend it.
Assessment has run over 5.8 years, from 22 Jan 2020 at AWMSG (Wales) to 19 Oct 2025 at NYE METODER (Norway).
NYE METODER (Norway) changed its position: not recommended on 24 Aug 2025, restricted by 19 Oct 2025, after a resubmission.
No assessment is on file from PBAC (Australia), PHARMAC (New Zealand) and CIPM (Spain), each among the eight highest-volume agencies here.
The file is active: 3 of 13 records date from 2023 or later.
4 distinct indication wordings are recorded for solriamfetol by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess solriamfetol, on 22 Jan 2020; NYE METODER (Norway) did not open a file until 24 Aug 2025 — a wide spread of 5.6 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 6 of 13 dated records fall in 2022 alone.
Restriction is doing real work here: 3 of 9 decisive outcomes narrowed solriamfetol to a subgroup rather than accepting or refusing it outright, at NYE METODER (Norway), SMC (Scotland) and TLV (Sweden).
5 of the 8 agencies here assessed solriamfetol more than once, NYE METODER (Norway) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for solriamfetol.
The full ledger for solriamfetol reads 4 not recommended, 3 restricted, 2 no benefit and 2 recommended, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 24 Aug 2025 | Bedring av våkenhet og reduksjon av uttalt søvnighet på dagtid hos voksne pasienter med narkolepsi (med eller uten katap… | not introduced | source |
| TLV (Sweden) | 12 Jul 2024 | Sunosi ingår i högkostnadsskyddet med förmånsbegränsning | restricted subsidy | source |
| ZIN (Netherlands) | 23 Dec 2022 | GVS-advies solriamfetol (Sunosi®) voor de behandeling van narcolepsie of obstructieve slaapapneu (OSA) | not reimbursed (GVS) | source |
| SMC (Scotland) | 11 Jul 2022 | To improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with narcolepsy (with or without cataplexy). | accepted (restricted) | source |
| G-BA (Germany) | 18 Mar 2022 | Sunosi — benefit assessment §35a | added benefit: not proven | source |
8 further decisions for solriamfetol, across 6 agencies, are not shown here. They include the most recent record on file, 19 Oct 2025 from NYE METODER (Norway); its outcome is in the subscriber dataset. They link to 8 further source documents.
Related molecules
- methylphenidate — same ATC class N06B — Psychoanaleptics
- idebenone — same ATC class N06B — Psychoanaleptics
- piracetam — same ATC class N06B — Psychoanaleptics
- lisdexamfetamine — same ATC class N06B — Psychoanaleptics
- modafinil — same ATC class N06B — Psychoanaleptics
- atomoxetine — same ATC class N06B — Psychoanaleptics
Coverage: 13 decisions for solriamfetol from 8 agencies, 2020 to 2025. Data to 7 Sep 2026. ATC class N06B — Psychoanaleptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.